Assessment of Efficacy and Safety of Metabolic Therapy With Trimetazidine MB in Patients With Ischemic Heart Disease and Chronic Heart Failure

被引：3

作者：

Gorbunova, M. L. ^{[1
]}

Vilkov, A. V. ^{[2
]}

机构：

[1] Nizhny Novgorod State Med Acad, Nizhnii Novgorod, Russia

[2] Nizhny Novgorod Cardiac Surg Ctr Corall, Nizhnii Novgorod, Russia

来源：

KARDIOLOGIYA | 2016年 / 56卷 / 03期

关键词：

ischemic heart disease; oxidative stress; metabolic therapy; trimetazidine MB;

D O I：

10.18565/cardio.2016.3.67-72

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Study purpose to assess clinical and hemodynamic parameters in patients with ischemic heart disease (IHD) with and without use of metabolic therapy with trimetazidine MB. Materials. Seventy four patients with IHD, 40 of whom in addition to the main therapy for 3 months received metabolic preparation trimetazidine MB. Results. Number of anginal attacks and inhalations of nitroglycerin significantly decreased and parameters of hemodynamics improved after 3 months in patients who received trimetazidine MB. Conclusion. Long-term use of trimetazidine MB in patients with IHD is advisable.

引用

页码：67 / +

页数：6

共 26 条

[11] Kondrashova M.N., 2002, PROBLEMS BIOL MED PH, V1, P7
[12] Kosarev V.V., 2013, CONSILIUM MED, V15, P34
[13] Kotov A.S., 2013, COGNITIVE DISORDERS
[14] Lukyanova L.D., 2004, PROBLEMS HYPOXIA MOL
[15] Makolkin V.I., 2004, CONSILIUM MED, V5
[16] Cardioprotective effects of trimetazidine: a review
Marzilli, M
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (07) : 661 - 672
[17] Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes - The MERLIN-TIMI 36 randomized trial
Morrow, David A.
Scirica, Benjamin M.
Karwatowska-Prokopczuk, Ewa
Murphy, Sabina A.
Budaj, Andrzej
Varshavsky, Sergei
Wolff, Andrew A.
Skene, Allan
McCabe, Carolyn H.
Braunwald, Eugene
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (16): : 1775 - U3
[18] Napalkov D.A., 2013, PHARMATECA, V6, P111
[19] Odinak M.M., 2010, J NEUROL PSYCHIAT, V12, P29
[20] Role of metabolically active drugs in the management of ischemic heart disease
Schofield R.S.
Hill J.A.
[J]. American Journal of Cardiovascular Drugs, 2001, 1 (1) : 23 - 35

← 1 2 3 →